CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced that their novel antibody drug conjugate, CPO301, received Fast Track Designation from the US FDA for treating a specific form of lung cancer. This marks the second such designation for CPO301, aiming to accelerate the drug’s development in the US market. The medication has shown promise in Phase I trials, offering potential new treatment options for patients with recurrent or metastatic squamous non-small cell lung cancer.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
